George Revtyak
Interventional Cardiology · Indianapolis, INNPI 1902867286
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Cardiovascular Systems Inc. accounts for 79.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $25,561 and has fallen 67.7% since, to $8,245 in 2025. Among interventional cardiology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $494.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$36K
- Edwards Lifesciences$8K
- Boston Scientific$279
- Abiomed$214
- Abbott$141
- AstraZeneca$89
- plus $272 from 8 others
Across 1 payment — averaging $5055.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$5K
What the payments were for
- Consulting fees$15,15834%
- Speaking & faculty fees$25,61357%
- Travel & lodging$2,1005%
- Food & beverage$2,0955%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 42 | $35,725 |
| Edwards Lifesciences | 7 | $8,245 |
| Boston Scientific | 14 | $279 |
| Abiomed | 3 | $214 |
| Abbott | 5 | $141 |
| AstraZeneca | 5 | $89 |
| Medtronic(2 entities) | 5 | $79 |
| Terumo Medical Corporation | 3 | $74 |
| Cardiva Medical, Inc. | 1 | $36 |
| Amgen | 2 | $35 |
| Teleflex LLC | 1 | $15 |
| Cardinal Health 200 LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Penumbra, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,965 in reported general payments places this provider in the 90th percentile of 170 interventional cardiology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $20,608 |
| ClopidogrelClopidogrel Bisulfate | 28 | $248 |
| Metoprolol Succinate | 14 | $189 |
| Atorvastatin Calcium | 14 | $109 |
| Amlodipine Besylate | 13 | $45 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Indianapolis
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Michael BallIndianapolis$76K
- Anjan SinhaIndianapolis$54K
- Nitesh GadeelaIndianapolis$48K
- Scott SharpIndianapolis$41K
- Amrish MalhiIndianapolis$37K
- Jeffrey BreallIndianapolis$21K
- Sandeep DubeIndianapolis$21K
- Kevin BallIndianapolis$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.